Phase 3 data in hand but adcomm voted 9-3 against effectiveness; PDUFA approval would vindicate the resubmission, a second CRL ends it

Bull

FDA overrides the advisory committee and grants approval, citing the statistically significant HOPE-3 primary endpoint (54% slowing of upper limb decline, p=0.03), the cardiac MRI fibrosis reduction data, and five-year HOPE-2 OLE durability — all of which passed peer review in The Lancet. Approval would trigger a Rare Pediatric Disease Priority Review Voucher with meaningful monetization value, validate the manufacturing facility already cleared in the Pre-License Inspection, and establish Deramiocel as the first approved therapy specifically targeting DMD cardiomyopathy.

Bear

FDA follows the 9-3 adcomm recommendation and issues a second Complete Response Letter, most likely citing insufficient evidence of clinical meaningfulness of the PUL 2.0 endpoint improvement, concerns about the magnitude of cardiac benefit, or residual data interpretation disputes flagged in the FDA briefing document — the same issues that drove the panel vote. A second CRL would, per the investment thesis, effectively end the program, and the contingency-based headquarters lease termination and ongoing NS Pharma litigation would compound the fallout.